SENS Earnings

SENS reported its FY2025Q3 earnings on 2025-11-05, showcasing a revenue of 8.00M against an estimate of 8.00M, resulting in a 1.54% surprise. The EPS was -0.43, surpassing the expected -0.33 by -30.3% . The stock experienced a -7.58% price change on the earnings day and a -3.27% change over the next five days, reflecting market reactions to the results.

Following SENS's FY2025Q3 earnings announcement on 2025-11-05, the stock price moved by -7.58% on the day of the release. Over the subsequent five days, it saw a -3.27% change. Historically, SENS's stock price tends to shift by an average of +9.89% in the 10 days leading up to earnings and -15.32% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SENS’s annual revenue to reach 14.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -2.65% and EPS estimates Revise Downward by -3.16% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SENS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -2.65%, while EPS estimates moved Revise Downward by -3.16% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SENS's stock price typically moves by +9.89% in the 10 days before its earnings and -15.32% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 14.00M.

The earnings call highlights strong financial performance with improved gross margins and reduced net loss. The company is expanding its market presence with product launches in Europe and increased DTC marketing spend. Despite some uncertainties in timelines and payer transitions, the guidance is optimistic with expected patient growth and revenue. Positive trends in patient acquisition and competitive dynamics further support a positive outlook. The Q&A section indicates management's confidence in growth opportunities, although some details were vague. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.